| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00540995 Details | 2023-11-30 Interventional | 1/2 | 25 | Busulfan Etoposide Etoposide phosp… Podophyllotoxin Anemia, Refract… Anemia, Refract… Blast Crisis Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Recurrence Syndrome Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Blastic Phase C… Childhood Acute… Childhood Chron… Childhood Myelo… Previously Trea… Recurrent Adult… Recurrent Child… Refractory Anem… | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic
than FTBI. Likely due to the giving of Busulfan prior to radiation delivery. Therefore, the
study was abandoned and no further patients were accrued. - | |||
| NCT05644626 Details | 2023-11-29 Interventional | 1 | 0 | Tislelizumab Neoplasms Solid Tumors | Sponsor determined the data was no longer needed. - | |||
| NCT04007367 2019-002640-25 Details | 2023-11-29 Interventional | 3 | 53 | Zuranolone Depression Depressive Diso… Depressive Diso… Major Depressiv… | Internal company decision The study was stopped prematurely and therefore data was not collected and analyzed for any efficacy outcome measure planned for the DB Phase of the study. | |||
| NCT03867370 Details | 2023-11-29 Interventional | 1/2 | 40 | Lenvatinib Carcinoma Carcinoma, Hepa… Hepatocellular … | Enrollment is over, the study was completed - | |||
| NCT03771664 Details | 2023-11-29 Interventional | 3 | 87 | Zuranolone Depression Depressive Diso… Depressive Diso… Sleep Initiatio… Insomnia Major Depressiv… | internal company decision The study was terminated early due to sponsor's decision and there were no safety concerns. | |||
| NCT02780128 Details | 2023-11-29 Interventional | 1 | 66 | Ceritinib Neuroblastoma Cancer | The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular
aberrations made Part 2 (treatment) no longer feasible. - | |||
| NCT05284812 Details | 2023-11-28 Interventional | 2 | - | Vaccines Tuberculosis | It is planned to restart the clinical study after the completion of the clinical trial protocol
modification. - | |||
| NCT05065567 Details | 2023-11-28 Interventional | 2 | 38 | Droperidol Haloperidol Haloperidol dec… Ondansetron Hyperemesis Gra… Syndrome Vomiting Cyclic Vomiting… | Lost too many patients to follow up, unable to enroll enough patients - | |||
| NCT04158141 Details | 2023-11-28 Interventional | 3 | 16 | Carboplatin Cisplatin Pemetrexed Lung Neoplasms Mesothelioma Mesothelioma, M… Pleural Biphasi… Pleural Epithel… Stage I Pleural… Stage IA Pleura… Stage IB Pleura… Stage II Pleura… Stage IIIA Pleu… | Permanent Administrative Closure - | |||
| NCT04301011 Details | 2023-11-27 Interventional | 1/2 | 27 | Pembrolizumab Carcinoma Carcinoma, Squa… Melanoma Mesothelioma Mesothelioma, M… Oropharyngeal N… Squamous Cell C… Uterine Cervica… Cervical Cancer Cutaneous Squam… HPV Positive Or… Melanoma (Skin) Microsatellite … Oropharynx Canc… Renal Cell Carc… Solid Tumor | Sponsor decision - | |||
| NCT03119012 Details | 2023-11-27 Interventional | 4 | - | Aspirin Clopidogrel Ticagrelor Atherosclerosis Coronary Artery… Coronary Diseas… Myocardial Isch… Stents | cannot use bioabsorbable scaffold - | |||
| NCT02842424 Details | 2023-11-27 Interventional | 4 | - | Ramipril Intermittent Cl… Peripheral Arte… Peripheral Vasc… | IRB administratively closed protocol - | |||
| NCT02176863 2013-004503-39 Details | 2023-11-27 Interventional | 2/3 | 191 | Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Poliomyelitis Postpoliomyelit… Syndrome Post-polio Synd… | - - | |||
| NCT01720563 Details | 2023-11-27 Interventional | 2 | 17 | Leucovorin Tegafur Carcinoma Carcinoma, Squa… Fatigue Squamous Cell C… Cancer-related … | Change study drug dosage form - | |||
| NCT05115838 2021-003414-39 Details | 2023-11-24 Interventional | 2 | 0 | Islatravir Acquired Immuno… HIV Infections Immunologic Def… HIV Human Immunodef… | Business Reasons - | |||
| NCT04629209 Details | 2023-11-24 Interventional | 2 | 0 | TIC10 compound Glioblastoma | Change in approach to study. - | |||
| NCT03824327 Details | 2023-11-24 Interventional | 1 | - | Papaverine Carcinoma, Non-… Lung Non-Small … | Per an amendment - | |||
| NCT03496623 Details | 2023-11-24 Interventional | 3 | 188 | Pharmaceutical … Treprostinil Hypertension Hypertension, P… Lung Diseases Lung Diseases, … Pulmonary Disea… Chronic Obstruc… Pulmonary Hyper… | Sponsor's decision Per sponsor decision, the study was terminated early. Data were not collected for the secondary outcome measures due to study termination and lack of appropriate sample size. | |||
| NCT02168270 Details | 2023-11-24 Interventional | 1 | 4 | Ascorbic Acid Temozolomide Astrocytoma Glioblastoma Gliosarcoma Oligodendroglio… Anaplastic Astr… Anaplastic Olig… Anaplastic Olig… | - - | |||
| NCT05998941 Details | 2023-11-22 Interventional | 2 | 0 | Bevacizumab Carboplatin Paclitaxel Uterine Cervica… Cervical Cancer | Slow progress in development, the sponsor decided to withdraw and no longer proceed. - |